Failure to maintain adherence to HAART in a cohort of French HIV-positive injecting drug users

International Journal of Behavioral Medicine

Volumn 10, Issue 1, 2003, Pages 1-14

  Carrieri, M P ^a   Chesney, M A ^b   Spire, B ^a   Loundou, A ^a   Sobel, A ^c   Lepeu, G ^d   Moatti, J P ^a   Boirot, C ^e   Bouhnik, A D ^e   Cassuto, J P ^e   Dellamonica, P ^e   Dujardin, P ^e   Duran, S ^e   Gallais, H ^e   Gastaut, J A ^e   Marimoutou, C ^e   Mechali, D ^e   Moreau, J ^e   Negre M ^e   Obadia, Y ^e   Poizot Martin, I ^e   Pradier, C ^e   Rey, D ^e   Rouzioux, C ^e   Tremolieres F ^e   Vlahov, D ^e   more..

^a INSERM   (France)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HENRI MONDOR HOSPITAL   (France)

^d CENTRE HOSPITALIER D AVIGNON   (France)

^e NONE

Author keywords

Adherence failure; Depression; Highly active antiretroviral therapies (HAART); HIV; Injecting drug users (IDU)

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; COHORT ANALYSIS; FEMALE; FRANCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PSYCHOLOGICAL ASPECT; SELF REPORT; SOCIAL SUPPORT; SOCIOECONOMICS; TREATMENT FAILURE; WELLBEING;

EID: 0037233832     PISSN: 10705503     EISSN: None     Source Type: Journal    
DOI: 10.1207/S15327558IJBM1001_01     Document Type: Article

References (58)

1. Altice, F., & Friedland, J. (1998). The era of adherence to antiretroviral therapy. Annals of Internal Medicine, 129, 503-505.
2. Avants, S. K., Margolin, A., Warburton, L. A., Hawkins, K. A., & Shi, J. (2001). Predictors of nonadherence to HIV-related medication regimens during methadone stabilization. American Journal of Addiction, 10, 69-78.
3. Bangsberg, D. R., Hecht, F. M., Charlebois, E. D., Zolopa, A. R., Holodniy, M., Sheiner, L., et al. (2000). Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS, 14, 357-366.
4. Bangsberg, D. R., Perry, S., Charlebois, E. D., Clark, R. A., Roberston, M., Zolopa, A. R., et al. (2001). Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS, 15, 1181-1183.
5. Bassetti, S., Battegay, M., Furrer, H., Rickenbach, M., Flepp, M., Kaiser, L., et al. (1999). Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study. Journal of Acquired Immune Deficiency Syndromes, 21, 114-119.
6. Calabrese, L. H. (2001). Changing patterns of morbidity and mortality in HIV disease. Cleveland Clinical Journal of Medicine, 68, 105, 9-10, 12.
7. Carr, A., Samaras, K., Burton, S., Law, M., Freund, J., Chisholm, D. J., et al. (1998). A syndrome of peripheral lipodystrophy, hyperlipidaemia, and insulin resistance in patients receiving HIV protease inhibitors. AIDS, 12, F51-F58.
8. Carrieri, M., Cailleton, V., Le Moing, V., Spire, B., Dellamonica, P., Bouvet, E., et al. (2001). The dynamic of adherence to highly active antiretroviral therapy (HAART): Results from the French National APROCO cohort. Journal of Acquired Immune Deficiency Syndrome, 28, 232-239.
9. Catz, S. L., Kelly, J. A., Bogart, L. M., Benotsch, E. G., & McAuliffe, T. L. (2000). Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychology, 19, 124-133.
10. Chesney, M. A., Ickovics, J., Hecht, F. M., Sikipa, G., & Rabkin, J. (1999). Adherence: A necessity for successful HIV combination therapy. AIDS, 13, S271-S278.
11. Chesney, M. A., Ickovics, J. R., Chambers, D. B., Gifford, A. L., Neidig, J., Zwicki, B., et al. (2000). Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: The AACTG adherence instruments. Patient Care Committee and Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care, 12, 255-266.
12. Chesney, M. A., Morin, M., & Sherr, L. (2000). Adherence to HIV combination therapy. Social Science & Medicine, 50, 1599-1605.
13. Clumeck, N., Goebel, F., Rozenbaum, W., Gerstoft, J., Staszewski, S., Montaner, J., et al. (2001). Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA. AIDS, 15, 1517-1526.
14. Cook, R. L., Sereika, S. M., Hunt, S. C., Woodward, W. C., Erlen, J. A., & Conigliaro, J. (2001). Problem drinking and medication adherence among persons with HIV infection. Journal of General Internal Medicine, 16, 83-88.
15. Duong, M., Piroth, L., Peytavin, G., Forte, F., Kohli, E., Graypin, M., et al. (2001). Value of patient self-report and plasma human immunodeficiency virus protease inhibitor level as markers of adherence to antiretroviral therapy: relationship to virologic response. Clinical Infectious Diseases, 33, 386-392.
16. Duran, S., Saves, M., Spire, B., Cailleton, V., Sobel, A., Carrieri, P., et al. (2001). Failure to maintain long-term adherence to highly active antiretroviral therapy: The role of lipodystrophy. AIDS, 15, 2441-2444.
17. Duran, S., Solas, C., Spire, B., Carrieri, M. P., Fuzibet, J. G., Costagliola, D., et al. (2001). "Do HIV-infected injecting drug users over-report adherence to highly active antiretroviral therapy?" A comparison between patients' self-reports and serum protease inhibitor concentrations in the French Manif 2000 cohort study. AIDS, 15, 1075-1077.
18. Duran, S., Spire, B., Raffi, F., Walter, V., Bouhour, D., Taumot, J., et al. (2001). Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART. HIV Clinical Trials, 2, 38-45.
19. Eron, J. J., Yetzer, E. S., Ruane, P. J., Becker, S., Sawyer, G. A., Fisher, R. L., et al. (2000). Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection. AIDS, 14, 671-681.
20. Fuhrer, R., & Rouillon, F. (1989). La version française de l'echelle CES-D [Description and translation of the autoevaluation scale]. Psychiatrie et Psychobiologie, 4, 163-166.
21. Gifford, A. L., Bormann, J. E., Shively, M. J., Wright, B. C., Richman, D. D., & Bozzette, S. A. (2000). Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. Journal of Acquired Immune Deficiency Syndromes, 23, 386-395.
22. Gordillo, V., del Amo, J., Soriano, V., & Gonzalez-Lahoz, J. (1999). Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS, 13, 1763-1769.
23. Graham, N. M. (1998). Studies of antiretroviral therapy in the Multicenter AIDS Cohort Study. Journal of Acquired Immune Deficiency Syndrome & Human Retrovirology, 17, S9-S12.
24. Haubrich, R. H., Little, S. J., Currier, J. S., Forthal, D. N., Kemper, C. A., Beall, G. N., et al. (1999). The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group. AIDS, 13, 1099-107
25. Hogg, R. S., Heath, K. V., Yip, B., Craib, K. J., O'Shaughnessy, M. V., Schechter, M. T., et al. (1998). Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. The Journal of the American Medical Association, 279, 450-454.
26. House, J. (1981). Work, stress, and social support. Reading, MA: Addison-Wesley.
27. Hung, C. C., Chen, M. Y., Hsieh, S. M., Sheng, W. H., & Chang, S. C. (2000). Clinical spectrum, morbidity, and mortality of acquired immunodeficiency syndrome in Taiwan: A 5-year prospective study. Journal of Acquired Immune Deficiency Syndromes, 24, 378-385.
28. Johnston-Roberts, K., & Mann, T. (2000). Barriers to antiretroviral medication adherence in HIV-infected women. AIDS Care, 12, 377-386.
29. Kastrissios, H., Suarez, J., Katzenstein, D., Girard, P., Sheiner, L., & Blaschke, T. (1998). Characterizing patterns of drug-taking behavior with a multiple drug regimen in an AIDS clinical trial. AIDS, 12, 2295-2303.
30. Lerner, B., Gulick, R., & Dubler, N. (1998). Rethinking non-adherence: Historical perspectives on triple-drug therapy for HIV disease. Annals of Internal Medicine, 129, 573-578.
31. Levy, R. L. (1983). Social support and compliance: A selective review and critique of treatment integrity and outcome measurement. Social Science & Medicine, 17, 1329-1338.
32. Liang, K., & Zeger, S. (1986). Longitudinal data analysis using generalized linear models. Biometrika, 73, 13-22.
33. Lucas, G. M., Cheever, L. W., Chaisson, R. E., & Moore, R. D. (2001). Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. Journal of Acquired Immune Deficiency Syndromes, 27, 251-259.
34. Mannerheimer, S., Friedland, G., Matts, J., Chen, L., Child, C., McArthur, M., et al. (2000). Self-reported antiretroviral adherence correlates with HIV viral load and declines overtime. Presented at XIIIth International AIDS conference, Durban, 2-14, July 2000. Abstract TUORB421.
35. Max, B., & Sherer, R. (2000). Management of the adverse effects of antiretroviral therapy and medication adherence. Clinical Infectious Diseases, 30(Suppl 2), S96-S116.
36. Miller, L. G., & Hays, R. D. (2000). Adherence to combination antiretroviral therapy: Synthesis of the literature and clinical implications. The AIDS Reader, 10, 177-185.
37. Moatti, J., Spire, B., & Duran, S. (2000). A review of socio-behavioural studies on adherence to antiretroviral treatments: Beyond biomedical models? Revue d'Epidemiologie et de Santé Publique, 48, 182-197.
38. Moatti, J. P., Carrieri, M. P., Spire, B., Gastaut, J. A., Cassuto, J. P., & Moreau, J. (2000). Adherence to HAART in French HIV-infected injecting drug users: The contribution of buprenorphine drug maintenance treatment. The Manif 2000 study group. AIDS, 14, 151-155.
39. Molina, J. M., Ferchal, F., Rancinan, C., Raffi, F., Rozenbaum, W., Sereni, D., et al. (2000). Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients. Journal of Infectious Diseases, 182, 599-602.
40. Morse, E., Simon, P., Coburg, M., Hyssop, N., Greenspan, D., & Balson, P. (1991). Determinants of subject compliance within an experimental anti-HIV drug protocol. Social Science & Medicine, 32, 1161-1167.
41. Murri, R., Ammassari, A., Gallicano, K., De Luca, A., Cingolani, A., Jacobson, D., et al. (2000). Patient-reported nonadherence to HAART is related to protease inhibitor levels. Journal of Acquired Immune Deficiency Syndromes, 24, 123-128.
42. Ostrop, N. J., Hallett, K. A., Gill, M. J. (2000). Long-term patient adherence to antiretroviral therapy. Annals of Pharmacotherapy, 34, 703-709.
43. Paterson, D. L., Swindells, S., Mohr, J., Brester, M., Vergis, E. N., Squier, C., et al. (2000). Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medicine, 133, 21-30.
44. Pierret, J. (2000). Everyday life with AIDS/HIV: Surveys in the social sciences. Social Science & Medicine, 50, 1589-1598.
45. Pilisuk, M. (1978). Kinship, social networks, social support and health. Social Science & Medicine, 12, 273-280.
46. Roca, B., Gomez, C. J., & Arnedo, A. (1999). Stavudine, lamivudine and indinavir in drug abusing and non-drug abusing HIV-infected patients: Adherence, side effects and efficacy. Journal of Infection, 39, 141-145.
47. Schneiderman, N., Antoni, M. H., Saab, P. G., & Ironson, G. (2001). Health psychology: Psychosocial and biobehavioral aspects of chronic disease management. Annual Review of Psychology, 52, 555-580.
48. Sherer, R. (1998). Adherence and antiretroviral therapy in injection drug users. The Journal of the American Medical Association, 280, 567-568.
49. Singh, N., Squier, C., Sivek, C., Wagener, M., Nguyen, M., & Yu, V. (1996). Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: Prospective assessment with implications for enhancing compliance. AIDS Care, 8, 261-269.
50. Smith, M., Rapkin, B., Morrison, A., & Kammerman, S. (1997). Zidovudine adherence in persons with AIDS: The relationship of patients beliefs about medication to self-termination of therapy. Journal of General Internal Medicine, 12, 216-223.
51. Spire, B., Duran, S., Souville, M., Leport, C., Raffi, F., & Moatti, J. (2002). Adherence to highly active antiretroviral therapy (HAART) in HIV-infected patients: From a predictive to a dynamic approach. Social Science & Medicine, 54, 1481-1496.
52. Stein, M. D., Rich, J. D., Maksad, J., Chen, M. H., Hu, P., Sobota, M., et al. (2000). Adherence to antiretroviral therapy among HIV-infected methadone patients: effect of ongoing illicit drug use. American Journal of Drug & Alcohol Abuse, 26, 195-205.
53. Stone, V. E. (2001). Strategies for optimizing adherence to highly active antiretroviral therapy: Lessons from research and clinical practice. Clinical Infectious Diseases, 33, 865-872.
54. Swindells, S., Mohr, J., Justis, J. C., Berman, S., Squier, C., Wagener, M. M., et al. (1999). Quality of life in patients with human immunodeficiency virus infection: Impact of social support, coping style and hopelessness. International Journal of STDs & AIDS, 10, 383-391.
55. Wagner, G., & Rabkin, J. (2000). Measuring medication adherence: Are missed doses reported more accurately than perfect adherence. AIDS Care, 12, 405-408.
56. Wallston, B., Alagna, S., De Vellis, B., & De Vellis, M. (1983). Social support and physical health. Health Psychology, 2, 367-391.
57. Wasserman, S., & Faust, K. (1994). Social network analysis. Cambridge, UK: Cambridge University Press.
58. Wendel, C. S., Mohler, M. J., Kroesen, K., Ampel, N. M., Gifford, A. L., & Coons, S. J. (2001). Barriers to use of electronic adherence monitoring in an HIV clinic. Annals of Pharmacotherapy, 35, 1010-1015.